A Phase 3 interventional study of Dotarem (gadoterate meglumine) and Magnevist (gadopentetate dimeglumine) in Diagnostic Self Evaluation and Central Nervous System Diseases, sponsored by Guerbet. Completed at 52 sites in 11 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2019-04-18.
Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Central Nervous System Diseases with a site in United States — 40 open to participants now, 49 under way, 4 of them phase 3. Central Nervous System Diseases · United States.
Among the 193 studies in Central Nervous System Diseases with a site in United States, this one is the 15th largest by enrollment of the 164 interventional ones that give a count, is one of 9 that started in 2010, is one of 25 in phase 3, and was the 38th registered.
386 studies on the registry are indexed under Central Nervous System Diseases; 104 are open to participants now.
Browse Central Nervous System Diseases studies →40 of the 193 studies in Central Nervous System Diseases with a site in United States are open now. Recruiting first, the newest first:
Magnetic Tides · Sites in United States
Ages 18–80
Vima Therapeutics · Sites in United States, Canada
Ages 18–65
University of Texas Southwestern Medical Center · Sites in United States
Ages 3–25
Peter C. Gerszten, MD · Sites in United States
Ages 21–75 · Healthy volunteers
Black Diamond Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Central Nervous System Diseases studies recruiting now, 34 (45%) set no upper age limit and 21 (28%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 66 · Phase 3 29 · Phase 4 1
First in 2000; this study’s year is marked. 9 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 416 is above the median of 52 across 296 interventional studies indexed under Central Nervous System Diseases.
Median enrollment 50 across the 164 interventional studies, 78 across the 26 observational. Of the 127 that completed or were terminated, 68 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 193 have an industry lead sponsor. The 10 most frequent:
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Guerbet has 2 studies filed under Central Nervous System Diseases — fewer than ten, so there is no comparison to draw.
12 of the studies in Central Nervous System Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
| NCT02414178Washington University School of MedicineF 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) | 2027-01 |
| NCT07631078Magnetic TideskTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery (KULMINATE) Pilot | 2027-02-28 |
| NCT06330181Texas A&M UniversityVirtual Walking Therapy for Neuropathic Pain Following Incomplete Spinal Cord Injury | 2027-04 |
| NCT05897957BlueRock TherapeuticsContinued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01 | 2027-05 |
Add all 12 to your calendar (.ics) → With an account.
Among the 193 studies in Central Nervous System Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to look at the safety (what are the side effects)and efficacy (how well does it work) of Dotarem® when used in taking images of the brain / spine. The results will be compared to the results of MRI taken without Dotarem.
This is a study involving the use of Magnetic Resonance Imaging (MRI) contrast agents called Dotarem®. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Dotarem® when used for taking images of the brain and spine. The results of the MRI will be compared to the results of images taken without Dotarem®.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.
Drug: Dotarem (gadoterate meglumine)
Dotarem and Magnevist were randomised as 2:1 ratio
Drug: Magnevist (gadopentetate dimeglumine)
Pediatric patients were assigned to Dotarem group only.
Drug: Dotarem (gadoterate meglumine)
0.1 mmol/kg by body weight, single IV injection
Also known as: Dotarem
0.1 mmol/kg by body weight, single IV injection
Also known as: Magnevist
MRI Lesion Visualization (Border Delineation, Internal Morphology and Contrast Enhancement) at Patient Level for Both "Pre" and "Paired" Evaluation
To demonstrate the superiority of combined unenhanced and Dotarem enhanced MRI (PAIRED) compared to unenhanced MRI (PRE) in terms of lesion visualization. Unenhanced MRI refers to MRI before administration of contrast agent. Enhanced MRI refers to MRI after contrast agent injection. "Pre" refers to unenhanced MRI. "PAIRED" refer to combined unenhanced and enhanced MRI. The measure used a specific scale with 3-point levels to assess lesion visualization. At lesion level, the scale range is from 0 through 1 to 2. Score 0 means a worse outcome and score 2 means a better outcome. Patient score is the sum of all lesion scores. Up to 5 of the largest representative lesions were assessed. At patient level, the maximum score is 10, minimum score is 0.
Time frame: up to 24 hours
Image Quality Score
Image quality was evaluated for each lesion according to a 3-point scale with the following grades; poor (1), fair (2) or good (3), and an overall score per patient was calculated. At patient level, the maximum score is 3, minimum score is 1. Higher scores mean a better image quality.
Time frame: up to 24 hours
Diagnostic Confidence Score
Level of diagnostic confidence when evaluating the MRI modalities was graded using a 5-point scale as nil (1), poor (2), moderate (3), high (4) and excellent (5).
Time frame: up to 24 hours
Number of Lesions
The number of lesions for which observations could be made was calculated for each MRI modality and results are summarized per patient
Time frame: up to 24 hours
First patient First Visit : 16 Sept 2010 Last patient Last Visit : 16 Nov 2011 Locations: radiology departments
| Milestone | Dotarem (Gadoterate Meglumine) | Magnevist (Gadopentetate Dimeglumine) | Dotarem 2 (Gadoterate Meglumine) |
|---|---|---|---|
| Started | 245 | 119 | 38 |
| Completed | 240 | 117 | 36 |
| Not completed | 5 | 2 | 2 |
To demonstrate the superiority of combined unenhanced and Dotarem enhanced MRI (PAIRED) compared to unenhanced MRI (PRE) in terms of lesion visualization. Unenhanced MRI refers to MRI before administration of contrast agent. Enhanced MRI refers to MRI after contrast agent injection. "Pre" refers to unenhanced MRI. "PAIRED" refer to combined unenhanced and enhanced MRI. The measure used a specific scale with 3-point levels to assess lesion visualization. At lesion level, the scale range is from 0 through 1 to 2. Score 0 means a worse outcome and score 2 means a better outcome. Patient score is the sum of all lesion scores. Up to 5 of the largest representative lesions were assessed. At patient level, the maximum score is 10, minimum score is 0.
| units on a scale | Dotarem (Gadoterate Meglumine) - PRE | Dotarem (Gadoterate Meglumine) - PAIRED |
|---|---|---|
| Border Delineation Blinded Reader 1 | 1.06 ± 1.23 | 3.30 ± 2.64 |
| Border Delineation Blinded Reader 2 | 1.62 ± 1.43 | 4.49 ± 2.94 |
| Border Delineation Blinded Reader 3 | 1.43 ± 1.29 | 2.54 ± 2.30 |
| Internal Morphology Blinded Reader 1 | 0.97 ± 1.05 | 3.70 ± 2.63 |
| Internal Morphology Blinded Reader 2 | 1.76 ± 1.24 | 4.49 ± 2.93 |
| Internal Morphology Blinded Reader 3 | 1.45 ± 1.13 | 2.93 ± 2.30 |
| Contrast Enhancement Blinded Reader 1 | 0.01 ± 0.20 | 3.11 ± 2.52 |
| Contrast Enhancement Blinded Reader 2 | 0.01 ± 0.15 | 3.73 ± 2.67 |
| Contrast Enhancement Blinded Reader 3 | 0.01 ± 0.13 | 2.95 ± 2.44 |
Image quality was evaluated for each lesion according to a 3-point scale with the following grades; poor (1), fair (2) or good (3), and an overall score per patient was calculated. At patient level, the maximum score is 3, minimum score is 1. Higher scores mean a better image quality.
| units on a scale | Dotarem (Gadoterate Meglumine) - PRE | Dotarem (Gadoterate Meglumine) - PAIRED | Magnevist (Gadopentetate Dimeglumine) - PRE | Magnevist (Gadopentetate Dimeglumine) - PAIRED |
|---|---|---|---|---|
| Reader 1 | 1.41 ± 0.52 | 2.98 ± 0.20 | 1.42 ± 0.53 | 2.96 ± 0.26 |
| Reader 2 | 1.72 ± 0.45 | 3.00 ± 0 | 1.74 ± 0.44 | 2.98 ± 0.19 |
| Reader 3 | 2.00 ± 0.07 | 2.99 ± 0.11 | 1.99 ± 0.09 | 2.99 ± 0.09 |
Level of diagnostic confidence when evaluating the MRI modalities was graded using a 5-point scale as nil (1), poor (2), moderate (3), high (4) and excellent (5).
| units on a scale | Dotarem (Gadoterate Meglumine) - PRE | Dotarem (Gadoterate Meglumine) - PAIRED | Magnevist (Gadopentetate Dimeglumine) - PRE | Magnevist (Gadopentetate Dimeglumine) - PAIRED |
|---|---|---|---|---|
| Reader 1 | 3.04 ± 0.90 | 4.59 ± 0.64 | 3.11 ± 0.86 | 4.66 ± 0.64 |
| Reader 2 | 2.84 ± 0.61 | 4.89 ± 0.31 | 2.85 ± 0.59 | 4.92 ± 0.36 |
| Reader 3 | 3.47 ± 1.22 | 4.41 ± 0.98 | 3.59 ± 1.29 | 4.59 ± 0.81 |
The number of lesions for which observations could be made was calculated for each MRI modality and results are summarized per patient
| Number of lesions | Dotarem (Gadoterate Meglumine) - PRE | Dotarem (Gadoterate Meglumine) - PAIRED | Magnevist (Gadopentetate Dimeglumine) - PRE | Magnevist (Gadopentetate Dimeglumine) - PAIRED |
|---|---|---|---|---|
| Reader 1 | 1.97 ± 3.16 | 2.69 ± 4.71 | 1.98 ± 3.85 | 4.19 ± 10.54 |
| Reader 2 | 2.29 ± 3.69 | 3.16 ± 5.21 | 2.60 ± 5.42 | 4.50 ± 9.95 |
| Reader 3 | 1.97 ± 2.99 | 2.46 ± 4.53 | 2.15 ± 3.97 | 3.97 ± 10.02 |
Collected over Adverse events were collected from patient consent signature to the end of the last visits, maximum duration is 29 days.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dotarem (Gadoterate Meglumine ) | 0/240 (0%) | 0/240 (0%) | 12/240 (5%) |
| Magnevist (Gadopentetate Dimeglumine) | 0/117 (0%) | 1/117 (0.9%) | 9/117 (7.7%) |
| Dotarem 2 (Gadoterate Meglumine ) | 0/38 (0%) | 1/38 (2.6%) | 8/38 (21.1%) |
| Event | Dotarem (Gadoterate Meglumine ) | Magnevist (Gadopentetate Dimeglumine) | Dotarem 2 (Gadoterate Meglumine ) |
|---|---|---|---|
| hypoxiaRespiratory, thoracic and mediastinal disorders | 0/240 | 0/117 | 1/38 |
| neurological decompensationNervous system disorders | 0/240 | 0/117 | 1/38 |
| small intestine perforationGastrointestinal disorders | 0/240 | 1/117 | 0/38 |
| Event | Dotarem (Gadoterate Meglumine ) | Magnevist (Gadopentetate Dimeglumine) | Dotarem 2 (Gadoterate Meglumine ) |
|---|---|---|---|
| headacheNervous system disorders | 1/240 | 1/117 | 2/38 |
| blood urine presentInvestigations | 2/240 | 0/117 | 1/38 |
| nauseaGastrointestinal disorders | 3/240 | 0/117 | 1/38 |
| dizzinessNervous system disorders | 1/240 | 0/117 | 1/38 |
| vomitingGastrointestinal disorders | 1/240 | 0/117 | 1/38 |
| astheniaGeneral disorders | 0/240 | 0/117 | 1/38 |
| application site erythemaGeneral disorders | 0/240 | 0/117 | 1/38 |
| hypoxiaRespiratory, thoracic and mediastinal disorders | 0/240 | 0/117 | 1/38 |
| pruritusSkin and subcutaneous tissue disorders | 0/240 | 0/117 | 1/38 |
| injection site hematomaGeneral disorders | 0/240 | 3/117 | 0/38 |
| Age, Categorical(Participants) | Magnevist (Gadopentetate Dimeglumine) | Dotarem (Gadoterate Meglumine) | Dotarem 2 (Gadoterate Meglumine) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 38 | 38 |
| Between 18 and 65 years | 89 | 185 | 0 | 274 |
| >=65 years | 30 | 60 | 0 | 90 |
| Age, Continuous(years) | Magnevist (Gadopentetate Dimeglumine) | Dotarem (Gadoterate Meglumine) | Dotarem 2 (Gadoterate Meglumine) | Total |
|---|---|---|---|---|
| Mean | 55.95 ± 14.43 | 53.17 ± 14.35 | 9.29 ± 4.49 | 49.8 ± 19.0 |
| Sex: Female, Male(Participants) | Magnevist (Gadopentetate Dimeglumine) | Dotarem (Gadoterate Meglumine) | Dotarem 2 (Gadoterate Meglumine) | Total |
|---|---|---|---|---|
| Female | 65 | 131 | 22 | 218 |
| Male | 54 | 114 | 16 | 184 |
| Region of Enrollment(participants) | Magnevist (Gadopentetate Dimeglumine) | Dotarem (Gadoterate Meglumine) | Dotarem 2 (Gadoterate Meglumine) | Total |
|---|---|---|---|---|
| United States | 30 | 65 | 17 | 112 |
| France | 13 | 30 | 0 | 43 |
| Argentina | 12 | 22 | 14 | 48 |
| Brazil | 5 | 8 | 4 | 17 |
| Spain | 2 | 8 | 0 | 10 |
| Austria | 10 | 20 | 0 | 30 |
| Chile | 3 | 5 | 3 | 11 |
| Germany | 20 | 40 | 0 | 60 |
| United Kingdom | 3 | 6 | 0 | 9 |
| Italy | 7 | 15 | 0 | 22 |
| Korea, Republic of | 14 | 26 | 0 | 40 |
The record gives a start of Sep 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadoterate meglumine
Central Nervous System Diseases →